A major advancement in the treatment of chronic myeloid leukemia (CML) has been the development of imatinib and other BCR-ABL tyrosine kinase inhibitors. MicroRNAs (miRNAs) are small RNA molecules that influence gene expression by post-transcriptional regulation of messenger RNA. It is not yet clear how miRNAs are able to regulate the effectiveness of imatinib in CML. Here, we show that imatinib markedly inhibits expression of miR-30a in human CML cells. miR-30a is a potent inhibitor of autophagy by downregulating Beclin 1 and ATG5 expression. miR-30a mimic or knockdown of autophagy genes (ATGs) such as Beclin 1 and ATG5 by short hairpin RNA enhances imatinib-induced cytotoxicity and promotes mitochondria-dependent intrinsic apoptosis. In contrast, knockdown of miR-30a by antagomir-30a increases the expression of Beclin 1 and ATG5, and inhibits imatinib-induced cytotoxicity. These findings indicate that dysregulation of miR-30a may interfere with the effectiveness of imatinib-mediated apoptosis by an autophagy-dependent pathway, thus representing a novel potential therapeutic target in CML.
INTRODUCTION
Imatinib, a targeted competitive inhibitor of the BCR-ABL tyrosine kinase, has revolutionized the clinical treatment of chronic myelogenous leukemia (CML). 1 However, resistance to imatinib has become an emerging problem that limits the long-term benefits of the drug in many patients with CML. Recent studies suggest that targeting autophagy, a lysosomal degradation pathway, may represent a novel strategy for modulating imatinib resistance in CML cells including the CML stem cells. 2 --4 In addition to performing homeostatic functions, such as protein and organelle turnover at basal levels, autophagy has pro-survival functions for cancer cells during cytotoxic insults such as starvation, hypoxia and in response to chemotherapy. 5 The study of autophagy is rapidly expanding, particularly within the field of translational cancer research. 6, 7 However, the mechanism of autophagy-mediated drug resistance remains largely uncertain and strategies for targeting autophagy remain challenging.
MicroRNAs (miRNAs) are a new class of small, non-proteinencoding RNAs that range in size from 19 to 25 nucleotides and have important roles in a variety of biological processes. 8 They are post-transcriptional regulators that bind to complementary sequences on target messenger RNA transcripts (mRNAs), usually resulting in translational repression or gene silencing. 8 miRNAs have been linked to several cancers including hematological malignancies. 9 Dysregulation of miRNAs is associated with certain types of cancer and have been attributed the functions of both tumor suppressor and oncogene in different contexts. Additionally, the specific expression patterns of miRNAs in response to therapy also suggest that miRNAs may contribute to therapy resistance in different tumors including CML. 10 Recently, work on miRNAs has expanded our understanding of the regulation of autophagy. Autophagy genes (ATGs) encode proteins that are required for autophagy. For example, miRNA-101 (miR-101) blocks autophagy and increases 4-hydroxytamoxifen-induced cytotoxicity in breast cancer cells by regulating ATG expression, specifically ATG4D. 11 Other studies indicate that miRNA-30a (miR-30a) inhibits the expression of Beclin 1 (the mammalian homolog of yeast ATG6) 12, 13 and regulates rapamycin-induced autophagy in breast and lung cancer cells. 13 Therefore, it is interesting to investigate whether and how these miRNAs regulates effectiveness of imatinib therapy in CML cells. Here, we demonstrated that imatinib inhibits the expression of miR-30a, but not miR-101, in CML cells. The downregulation of miRNA-30a induces Beclin 1 and ATG5 expression and subsequently autophagy, which inhibits imatinib-induced intrinsic apoptosis. In contrast, upregulated miR-30a increases imatinibinduced cytotoxicity. Moreover, targeting miR-30a also potentiates imatinib-induced cell death in primary CML stem/progenitor cells.
Cell culture and patients
The human CML cell line K562 was obtained from American Type Culture Collection and cultured in Iscove's Modified Dulbecco's Medium (Life Technologies, Grand Island, NY, USA) with 10% heat-inactivated fetal bovine serum (bovine serum albumin) and 2 mM L-glutamine in a humidified incubator with 5% CO 2 and 95% air. Bone marrow mononuclear cells from CML patients were isolated by Ficoll (GE Healthcare, Piscataway, NJ, USA) density gradient centrifugation. The diagnosis of CML was made on the basis of clinical features, hematological characteristics and the presence of the Ph chromosome, which have been described in detail previously. 14 Briefly, the newly diagnosed childhood CML patients, who had adequate hepatic and renal function and no serious medical conditions, were eligible. The trial was approved by institutional review boards and ethics committees and all patients gave written informed consent in accordance with the Declaration of Helsinki. Samples were enriched for CD34 þ cells using CliniMACS (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions. The purity of CD34 þ was routinely above 95% as assessed by flow cytometric analysis as previously described.
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CD34 þ cells were cultured in X-vivo 15 (BioWhittaker, Walkersville, MD, USA) containing 1% bovine serum albumin, 2 mM L-glutamine and a cytokine cocktail (StemCell Technologies, Vancouver, BC, Canada).
miRNAs transfection and RNAi
Short hairpin RNA against human Beclin 1 and ATG5 were obtained from Sigma. The mimic and antagomir against human miR-30a were obtained from Dharmacon (Lafayette, CO, USA). These short hairpin RNAs and miRNAs were transfected into cells by lentiviral delivery systems according to the manufacturer's instructions.
Detailed protocols for all other methods are provided as Supplementary Information. miR-30a is a potent inhibitor of autophagy during imatinib treatment in CML cells Autophagy has been linked to imatinib resistance in CML cells.
RESULTS

Downregulation
2,3
To investigate whether miR-30a is a direct activator of autophagy, we detected microtubule-associated protein light chain 3 (LC3) conversions (LC3-I to LC3-II) by immunoblot analysis. LC3 is now widely used to monitor autophagy, and the amount of LC3-II correlates with the number of autophagosomes. 16 Treatment with miR-30 mimic inhibited imatinib-induced expression of LC3-II in K562 cells (Figure 3a) . Moreover, LC3 accumulation following miR-30 mimic treatment was exaggerated in K562 cells after treatment with the lysosomal protease inhibitor E64d and pepstatin A (E64D/ PA) ( Figure 3a ). These data demonstrate that the observed decrease in LC3-II was not due to increased degradation of LC3. In contrast, treatment with antagomir-30a increased imatinib-induced autophagic flux assayed by LC3-II turnover with or without E64D/PA ( Figure 3a) . As noted, antagomir-30a treatment also induces Beclin 1 expression, as well as autophagy, in the absence of imatinib treatment (Figure 3a) . It is unclear whether overexpression of Beclin 1 is sufficient to induce autophagy in cells where BCR-ABL is fully active. Additionally, we found that miR-30a mimic inhibited imatinib-induced LC3 puncta formation (Figure 3b ) by confocal microscopy and autophagic vacuole formation (Figure 3c ) by transmission electron microscopy, whereas antagomir-30a increased LC3 puncta formation (Figure 3b ). These findings suggest that miR-30a is a negative regulator of imatinib-induced autophagy in CML cells. Compared to the activation of Beclin 1, suppression of the mammalian target of rapamycin (mTOR) is an early event during autophagy, although mTOR-independent pathways exist. 17 Recently, it has been found that the overexpression of BCR-ABL suppresses autophagy through the regulation of mTOR transcription. 18 We found that the mTOR inhibitor rapamycin did not change miR-30a levels (Figure 3d) , and antagomir-30a also did not change mTOR mRNA level (Figure 3e ). Moreover, miR-30a mimic did not inhibit rapamycin-induced LC3 puncta formation (Figure 3f ). These Figure 2 . miR-30a regulates Beclin 1 and ATG5 expression in CML cells. (a --c) K562 cells were transfected with antagomir or mimic of miR-30a (100 nM) or non-target antagomir or mimic control (100 nM) for 48 h, and then treated with imatinib (0.5 mM) for 24 h. The level of miR-30a (a) was assayed by TaqMan qRT-PCR (n ¼ 3, *Po0.05 versus non-target control group). In parallel, the mRNA (b) and protein (c) level of indicated ATGs were assayed by qRT-PCR and western blot, respectively (n ¼ 3, *Po0.05 versus non-target control group). (d) Primary CML patient bone marrow mononuclear cells were transfected with mimic of miR-30a (100 nM) or non-target mimic control (100 nM) for 48 h, and then treated with imatinib (0.5 mM) for 24 h. The mRNA level of Beclin 1 and ATG5 were assayed by qRT-PCR (n ¼ 3, *Po0.05 versus non-target control group).
findings suggest that miR-30a regulates autophagy in an mTOR-independent manner. miR-30a regulates imatinib-induced cytotoxicity in CML cells The observed effects of miR-30a on autophagy suggest that an increase of cellular levels of miR-30a should make CML cells more susceptible to the imatinib. Imatinib-induced cytotoxicity and apoptosis in K562 or primary CML cell were measured by MTT cell viability assay and Annexin V staining by flow cytometry, respectively. miR-30a mimic significantly decreased cell viability and enhanced imatinib-induced apoptosis in these CML cells (Figures 4a and b) . Moreover, miR-30a mimic also inhibited autophagy and enhanced apoptosis in K562 cells when they were treated with other BCR/ABL tyrosine kinase inhibitors (for example, nilotinib and dasatinib) (Figure 4c) , suggesting a wide role of miR-30a in regulating the effectiveness of BCR/ABL tyrosine kinase inhibitors. In contrast, antagomir-30a increased autophagy and Figure 3 . miR-30a regulates autophagy in CML cells. (a) K562 cells were transfected with antagomir or mimic of miR-30a (100 nM) or non-target antagomir or mimic control (100 nM) for 48 h, and then treated with imatinib (0.5 mM) with or without E64D/ pepstatin A ('E64D/PA' , 10 mg/ml) for 24 h. The level of LC3-I/II protein expression was assayed by western blot. (b, c) K562 cells were transfected with antagomir or mimic of miR-30a (100 nM) or non-target antagomir or mimic control (100 nM) for 48 h, and then treated with imatinib (0.5 mM) for 24 h. The LC3 puncta formation (b) was assayed by confocal microscopic analysis and ultrastructural features of autophagic vacuoles (c) was assayed by TEM (*Po0.05 versus non-target control group). By definition, autophagic vacuoles are limited by a double or occasionally multi-layered membrane. 38 They contain cytoplasmic material or organelles. Sometimes the autophagic vacuoles membrane does not have any contrast in thin sections. This is probably caused by extraction of lipids during sample preparation, as lipids are not optimally preserved in conventional aldehyde fixation. 38 (c) Magnified autophagic vacuole of multiple membranes. (d) K562 cells were treated with imatinib and rapamycin as indicated for 24 h, and the levels of miR-30a were assayed by TaqMan qRT-PCR (n ¼ 3, *Po0.05 versus untreated group). (e) K562 cells were transfected with antagomir or mimic of miR-30a (100 nM) or non-target antagomir or mimic control (100 nM) for 48 h, and then the mRNA level of Beclin 1 and mTOR were assayed by qRT-PCR (n ¼ 3, *Po0.05 versus non-target control group). (f ) K562 cells were transfected with mimic of miR-30a (100 nM) or non-target mimic control (100 nM) for 48 h, and then treated with rapamycin (500 nM) for 24 h. The level of LC3-I/II protein expression was assayed by western blot. decreased apoptosis in K562 and primary CML cells after treatment with imatinib, nilotinib and dasatinib (Figure 4d ). To test if suppression of Beclin 1 and ATG5 also increased sensitivity to imatinib, we knocked down the expression of Beclin 1 and ATG5 in K562 cells by short hairpin RNA-mediated RNAi. Suppression of Beclin 1 and ATG5 expression (Figure 5a ) increased apoptosis after imatinib treatment (Figure 5b) . Importantly, knockdown of Beclin 1 and ATG5 restored the sensitivity to imatinib-induced apoptosis after treatment with antagomir-30a (Figure 5c ), suggesting that Beclin 1 and ATG5 are required for antagomir-30a-mediated drug resistance. miR-30a-mediated autophagy regulates imatinib-induced mitochondria-dependent apoptosis The intrinsic mitochondria-dependent apoptotic pathway functions in response to various types of intracellular stress including anticancer agents. We next investigated whether miR-30a-mediated autophagy regulates imatinib-induced mitochondrial pathway of apoptosis. Indeed, we found that miR-30a mimic as well as knockdown of Beclin 1 and ATG5 increased imatinibinduced intrinsic apoptotic events such as loss of mitochondrial membrane potential (DCm) (Figure 6a ), increased Bax mitochondrial translocation (Figure 6b ), increased cytochrome c release miR-30a -mediated Beclin 1 expression regulates imatinib-resistant in CML stem cells CML is a clonal hematopoietic disorder thought to arise from a pluripotent stem cell. 19 CML stem cells display resistance against imatinib. 20 Previous studies have shown that tyrosine kinase inhibitor treatment in combination with inhibition of autophagy results in the eradication of CML stem cells. 2 To determine whether miR-30a-mediated autophagy is a potential survival mechanism for CML stem cells, we measured miR-30a expression in CD34 þ CML stem and progenitor cells. Compared with CD34À cells, CD34 þ cells expressed lower levels of miR-30a, and a further decrease was observed after imatinib treatment (Figure 7a ). In contrast, the mRNA levels of Beclin 1 were increased in CD34 þ cells with or without imatinib treatment (Figure 7b) . Importantly, miR-30a mimic and knockdown of Beclin 1 by short hairpin RNA restored the sensitivity of CD34 þ cells to imatinib (Figure 7c ). These findings suggest that miR-30a-mediated Beclin 1 expression is required for imatinib-resistance in CML stem cells.
DISCUSSION
As a prototypical-targeted agent, imatinib (also known as STI-571) had a major impact on the treatment of patients with CML, because BCR-ABL is uniquely expressed by CML cells and is essential for their survival and proliferation. 1 However, CML cells can respond to imatinib in a variety of ways ranging from initiation of cell death to the activation of survival pathways such as autophagy. 21, 22 This survival pathway will limit imatinib-induced cell death and promote the formation of imatinib resistance. 2, 3, 23 In this study, we identified dysregulated miR-30a as an important event that mediated autophagy during imatinib treatment. Imatinib inhibits miR-30a, but not miR-101 and miR-32, expression in CML cells. A recent study has identified a group of 19 miRNAs including miR-30 family that may predict clinical resistance to imatinib in patients with newly diagnosed CML. 10 We found that downregulated miR-30a inhibits imatinib-induced cytotoxicity, whereas the upregulated miR-30a increases imatinib-induced cytotoxicity. These findings confirm the important role of deregulated miRNA in CML pathogenesis and chemotherapy resistance.
Our findings suggest that the pro-autophagic proteins Beclin 1 and ATG5 are targets of miR-30a in CML cells, which is partly consistent with previous studies that miR-30a negatively regulates Beclin 1 expression in solid cancer cells. 12, 13 However, it is of note that any given mRNA may be targeted by different miRNAs in different cell types. 24 Indeed, it has been shown that the integrin CD61 and the ubiquitin-conjugating E2 enzyme UBC9 are downregulated by miR-30 in breast cancer cells, 25 and p53 protein is a target of miR-30 in cardiomyocytes during oxidative stress.
26 p53 has a key role in ensuring that damaged cells are destroyed by apoptosis. It can also regulate autophagy by transcriptiondependent or independent pathways. 27 However, p53 is the most commonly mutated gene associated with cancer including leukemia. 28 Additionally, the myeloid-derived lines such as K562 do not express p53 protein. 29 Thus, we focus on the function and significance of miR-30a-mediated Beclin 1 and ATG5 expression in regulation of effectiveness of imatinib in CML cells.
Functional studies reveal that miR-30a, Beclin 1 and ATG5 have effects on imatinib-induced cell cytotoxicity. Beclin 1 is an essential autophagy protein that has been linked to multiple processes including tumor suppression, protection against some cardiac and neurological diseases, and lifespan extension. 30 It interacts with several cofactors (for example, ATG14L, UVRAG, Rubicon, Ambra1, HMGB1) to regulate the lipid kinase PI3KC3 protein and promote the formation of Beclin 1-PI3KC3 core complexes, thereby initiating autophagy. 31 Formation of the autophagosome involves a ubiquitin-like conjugation system in which ATG12 is covalently bound to ATG5 and targeted to autophagosome vesicles. 32 As a regulator of Beclin 1 and ATG5, miR-30a mimic inhibits expression of Beclin 1 and ATG5, and downregulates autophagy, whereas antagomir-30a increases their expression and autophagy. Moreover, knockdown of Beclin 1 and ATG5 inhibits antagomir-30a-induced autophagy, confirming that Beclin 1 and ATG5 are downstream effectors of miR-30a-mediated autophagy. Importantly, miR-30a mimic increased imatinib and other BCR/ABL tyrosine kinase inhibitor-induced cytotoxicity, providing a novel experimental strategy to enhance sensitivity of imatinib in CML cells. Mechanistic studies reveal that dysregulated miR-30a-mediated autophagy increases cell survival by regulating the intrinsic apoptotic pathway. Bax is a pro-apoptotic Bcl-2-family protein 33 that resides in the cytosol and translocates to mitochondria upon induction of apoptosis. 34, 35 Bax induces cytochrome c release, caspase-9 and -3 activation in vivo and in vitro. 34, 36 This cytochrome c release was reportedly dependent upon induction of the mitochondrial permeability transition, an event that is associated with the disruption of the mitochondrial inner transmembrane potential (DCm). 37 We found that miR-30a mimic as well as knockdown of Beclin 1 and ATG5, increased these mitochondrial apoptotic events. In contrast, antagomir-30a increased autophagy and inhibits loss of DCm and activation of caspase-9 during imatinib treatment, confirming that autophagy serves to protect against apoptosis.
In summary, autophagy is a process that allows cells to adapt to environmental stresses, and enables imatinib-treated CML cells to escape cell death. Our study suggests that downregulated miR30a mediates Beclin 1 and ATG5-dependent autophagy, which confers resistance to imatinib in treated CML cells. The molecular basis of autophagy action during this process is partly by regulation of the mitochondria-dependent intrinsic apoptotic pathway. These findings enhance the understanding of CML cell survival mechanisms during treatment with BCR/ABL tyrosine kinase inhibitors such as imatinib. Additional work is necessary to explore the side effects of interfering with miR-30a regulation in animals or humans, identifying other miR-30a target genes, the role of these proteins in regulating imatinib resistance and the relationship between autophagy and other drug-resistance mechanisms. 
